Biomarkers of Alzheimer’ disease (AD) could be established by analysis of neurofibrillary tangle related pathology. Microtubule associated tau is abnormally phosphorylated (p-tau) in AD and aggregates in neurofibrillary tangles. Immunoassays have been developed detecting tau at specific phosphorylated epitopes in CSF. P-tau was highly increased in AD compared to healthy subjects and differentiated AD from its most relevant differential diagnoses. Specificity and sensitivity levels range over 80%. P-tau levels declined with disease progression, correlating with cognitive performance at baseline. Mild cognitively impaired patients showed elevated p-tau baseline levels, correlating with rate of cognitive decline. Cumulative data indicates that CSF p-tau improves early detection, differential diagnosis and tracking of disease progression in AD.
Hampel, H. et al. Ann Neurol 49 (2001) p. 545–546
Bürger, K. et al. Am J Psychiatry 160 (2003) p. 376–379
Hampel, H. et al. Arch Gen Psychiatry (2003) in press
